Pak inhibitors and methods for the treatment of cell proliferation disorders and / or central nervous system disorders. 1. Property 1: compound (1) with formula structure property,Formula (2),Or formula (3),or a pharmaceutically acceptable salt or N-oxide thereof, wherein: the T ring is an aryl or heteroaryl ring； R¹ is H, or substituted or unsubstituted alkyl； R² is unsubstituted alkyl or substituted or unsubstituted amino substituted alkyl, amido, nitro, arylthio, alkylsulfoxide, arylsulfoxide, alkylsulfone, arylsulfone, aryloxy, alkoxy, amide, ester, alkoxy, cyano, aryl, or heteroaryl； substituted or unsubstituted alkoxy； substituted or unsubstituted aralkoxy； substituted or unsubstituted heteroalkyl； substituted or unsubstituted cycloalkyl； substituted or unsubstituted cycloalkylalkyl； substituted or unsubstituted heterocycloalkyl；a. Keywords substituted or unsubstituted isocycloclalquil； helix cyclopropyl isocyclopropyl； tar-s (= O) r8313；-Asphalt-s (= O) 8322； - r8313；o -S (3DO) RR3 is h, substituted or unsubstituted tar, substituted or unsubstituted alcox, substituted or unsubstituted ammonia, substituted or unsubstituted isopropyl benzene, substituted or unsubstituted isopropyl gas, substituted or unsubstituted cyclopropenyl, substituted or unsubstituted cyclohexaclarge, substituted or unsubstituted isopropyl methanol, a. Arilo replaced or not replaced, aralquilo replaced or not replaced, heterosexual replaced or not replaced, or heterosexual replaced or not replaced； r830808 is heterosexual replaced or not replaced by r830808 carbon atom；a. Using r830808 carbon atom, replacing or not replacing t-ring or phenyl ring；Each r83099 is an independent halogen, N, no832222,-Oh, ocf83233,-OCH F -OCF H -CF-831222,-8304； s (= O) 8322； r8313,-S (3DO) N (R)-S (3DO) R-S (3DO) R-C (3DO) R-OC (3DO) R-CO₂R¹⁰,-N (R)-C (3DO) N (R)-No. 830404； (= O) r1830404,-830404； (= O) or1830404,NR C (3DO) N (R)e. Alternative or unsubstituted asphalt； alternative or unsubstituted acoxi； al
